drugset
drugset / Trial / NCT04231526

Pembrolizumab in Early Stage Colon Cancer

NCT04231526 ↗

Phase 2 Withdrawn University of Chicago Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will gather information on the safety and effectiveness of pembrolizumab, an immunotherapy drug. The purpose of this study is to target early stage colon cancer before it has developed resistance to immunotherapy.

Timeline

Start
2020-05-20
Primary completion
2022-12-01
Completion
2022-12-01

Outcome

Outcome not reported

Stopped (Enrollment): “unable to accrue”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

colon carcinoma